Reuters logo
BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline
September 11, 2017 / 11:05 AM / 9 days ago

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

Sept 11 (Reuters) - Tetraphase Pharmaceuticals Inc:

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

* Tetraphase Pharmaceuticals Inc - ‍company expects to report top-line data from trial in Q1 of 2018.​

* Tetraphase Pharmaceuticals Inc - ‍plan to file a supplemental nda (snda) for iv eravacycline as a new treatment for patients with CUTI​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below